Ursodeoxycholic acid

1. Hempfling W, Dilger K, Beuers U. Ursodeoxycholic acid – adverse effects and drug interactions. Aliment Pharmacol Ther 2003; 18 (10): 963–972.

2. Beuers U, Trauner M, Jansen P et al. New paradigms in the treatment of hepatic cholestasis. From UDCA to FXR, PXR and beyond. J Hepatol 2015; 62 (Suppl 1): S25–S37. doi: 10.1016/j.jhep.2015.02.023.

3. Roma MG, Toledo FD, Boaglio AC et al. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci (Lond) 2011; 121 (12): 523–544. doi: 10.1042/CS20110184.

4. Chiang JY. Bile acids: regulation of synthesis. J Lipid Res 2009; 50 (10): 1955–1966. doi: 10.1194/jlr.R900010-JLR200.

5. Státní ústav pro kontrolu léčiv. Souhrn údajů o přípravku Ursosan 2014. [online]. Dostupné z: www.sukl.cz/modules/medication/detail.php?code=00138 08&tab=texts.

6. Doporučený postup České hepatologické společnosti ČLS JEP. PBC (primární biliární cirhóza) a PSC (primární sklerozující cholangoitida). Česká hepatologická společnost 2010: 1–19. [online]. Dostupné z: www.ces-hep.cz/file/325/doporuceny-postup-chs-pbc-a-psc.pdf.

7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51 (2): 237–267. doi: 10.1016/j.jhep.2009.04.009.

8. Nunes D. Dissolution therapy for the treatment of gallstones. UpToDate. [online]. Available from: www.uptodate.com/contents/dissolution-therapy-for-the-treat-ment-of-gallstones.

9. Guarino M, Cocca S, Altomare A et al. Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World J Gastroenterol 2013, 19 (31): 5029–5034. doi: 10.3748/wjg.v19.i31.5029.

10. Shah H, Mandukhal S, Gilani A et al. Effect of ursodeoxycholic acid (UDCA) therapy on gallbladder motility in cholesterol gallstone patients. Am J Gastroenterol 2012; 107 (Suppl 1): S73.

11. Chen W, Liu J, Gluud C. Bile acids for viral hepatitis. Cochrane Database Syst Rev 2007; 4: CD003181.

12. Wijaya I. The Role of ursodeoxycholic acid in acute viral hepatitis: an evidence-based case report. Acta Med Indones 2015, 47 (4): 352–357.

13. Verma S, Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut 2009, 58 (11): 1555–1564. doi: 10.1136/gut.2008.163675.

14. Sabariah NH, Siti MS, Nor AC et al. Cholestatic hepatitis secondary to carbamazepine treatment with ursodeoxycholic acid – a case report. Trop J Pharm Res 2014; 13 (10): 1745–1747.

15. Xiang Z, Chen YP, Ma KF et al. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol 2013; 13: 140. doi: 10.1186/1471-230X-13-140.

16. Carr RM, Reid AE. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr Atheroscler Rep 2015, 17 (4): 500. doi: 10.1007/s11883-015-0500-2.

17. Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis 2007; 16 (1): 39–46.

18. Ratziu V. Treatment of NASH with ursodeoxycholic acid: pro. Clin Res Hepatol Gastroenterol 2012; 36 (Suppl 1): S41–S45. doi: 10.1016/S2210-7401 (12) 70020-7.

19. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‚mechanisms of action and clinical use in hepatobiliary disorders‘. J Hepatol 2001; 35 (1): 134–146.

20. Fickert P, Zollner G, Fuchsbichler A et al. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterol 2001; 121 (1): 170–183.

21. Zollner G, Wagner M, Moustafa T et al. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol 2006; 290 (5): G923–G932.

22. Zollner G, Wagner M, Trauner M. Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. Pharmacol Ther 2010; 126 (3): 228–243. doi: 10.1016/j.pharmthera.2010.03.005.

23. Micheline D, Emmanuel J, Serge E. Effect of ursodeoxycholic acid on the expression of the hepatocellular bile acid transporters (Ntcp and bsep) in rats with estrogen-induced cholestasis. J Pediatr Gastroenterol Nutr 2002; 35 (2): 185–191.

24. Schuetz EG, Strom S, Yasuda K et al. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome p450. J Biol Chem 2001; 276 (42): 39411–39418.

25. Concepcion AR, Lopez M, Ardura-Fabregat A et al. Role of AE2 for pH (i) regulation in biliary epithelial cells. Front Physiol 2014; 4: 413. doi: 10.3389/fphys.2013.00413.

26. Buryova H, Chalupsky K, Zbodakova O et al. Liver protective effect of ursodeoxy- cholic acid includes regulation of ADAM17 activity. BMC Gastroenteroly 2013, 13: 155. doi: 10.1186/1471-230X- 13-155

27. Azzaroli F, Mehal W, Soroka CJ et al. Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes. Hepatology 2002; 36 (1): 49–54.

28. Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012, 36 (Suppl 1): S3–S12. doi: 10.1016/S2210-7401 (12) 70015-3.

29. Corpechot C, Carrat F, Bonnand AM et al.The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32 (6): 1196–1199.

30. Tay J, Tinmouth A, Fergusson D et al. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13 (2): 206–217.

31. Dynamed. Ursodiol. In: EBSCO 2016. [online]. Available from: http: //web.a.ebs cohost.com/dynamed/detail?vid=2&sid=f26b9687-6f75-4976-afcd-e8f705 da8691%40sessionmgr4009&hid=4206& bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#AN=526120&db=dme.

32. Crosignani A, Setchell KD, Invernizzi P et al. Clinical pharmacokinetics of therapeutic bile acids. Clin Pharmacokinet 1996; 30 (5): 333–358.

33. Stiehl A, Rudolph G, Sauer P et al. Billiary secretion of bile acids and lipids in primary sclerosing cholangitis – influence of cholestasis and effect of ursodeoxycholic acid treatment. J Hepatol 1995, 23 (3): 283–289.

34. Sackmann M, Pauletzki J, Aydemir U et al. Efficacy and safety of ursodeoxycholic acid for dissolution of gallstone fragments – comparison with the combination of ursodeoxycholic acid and chenodeoxycholic acid. Hepatology 1991; 14 (6): 1136–1141.

35. Singh S, Khanna S, Pardi DS et al. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. A systematic review and meta-analysis. Inflamm Bowel Dis 2013; 19 (8): 1631–1638. doi: 10.1097/MIB. 0b013e318286fa61.

36. Gabzdyl E, Schlaeger JM. Intrahepatic cholestasis of pregnancy a critical clinical review. J Perinat Neonatal Nurs 2015; 29 (1): 41–50. doi: 10.1097/JPN.0000000000000077.

37. Rudi J, Schönig T, Stremmel W. Therapy with ursodeoxycholic acid in primary biliary cirrhosis during pregnancy. Z Gastroenterol 1996; 34 (3): 188–191.